Presentation is loading. Please wait.

Presentation is loading. Please wait.

AMG 176 exhibits robust single-agent activity in vivo.

Published byOsman Suvari Modified over 4 years ago

Similar presentations

Presentation on theme: "AMG 176 exhibits robust single-agent activity in vivo."— Presentation transcript:

1 AMG 176 exhibits robust single-agent activity in vivo.
AMG 176 exhibits robust single-agent activity in vivo. A, Time- and dose-dependent effects of AMG 176 treatment on apoptotic markers (activated BAK, cleaved caspase-3, and cleaved PARP) in established OPM-2 luc tumors as measured in MSD immunoassays. B, Effects of AMG 176 on established OPM-2 luc tumor xenografts when dosed daily or on a 2-day on, 5-day off schedule. C, Effects of AMG 176 on established OPM-2 luc tumor xenografts when dosed once weekly. D, Effects of AMG 176 on MOLM13 luc orthotopic tumor xenografts when dosed on a 2-day-on, 5-day-off schedule. Representative day 15 bioluminescence images are shown. For xenograft studies, mean tumor volume or whole-body luminescence (dorsal + ventral image) ± SEM (n = 10/group) are reported. ***, P < (RMANOVA with Dunnett post hoc). E, Flow cytometry assessment of B cells, monocytes, and neutrophils in peripheral blood and bone marrow of human MCL1 knock-in mice following administration of AMG hours after cycle 1 (day 3) and cycle 2 (day 10). *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < (one-way ANOVA with Dunnett post hoc). Sean Caenepeel et al. Cancer Discov 2018;8: ©2018 by American Association for Cancer Research

Download ppt "AMG 176 exhibits robust single-agent activity in vivo."

Similar presentations

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.

Combined RAF and EGFR inhibition leads to improved in vivo efficacy in BRAF-mutant colorectal cancer. Combined RAF and EGFR inhibition leads to improved.
CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.

CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.
Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.

Treatment with BLU9931 leads to tumor regression in the FGF19-overexpressing PDX-derived xenograft LIXC012. Treatment with BLU9931 leads to tumor regression.
Supplementary Figure S13

Supplementary Figure S13
AG-221 induces the differentiation of IDH2R140Q blasts along myeloid lineages in primary human AML xenograft models. AG-221 induces the differentiation.

AG-221 induces the differentiation of IDH2R140Q blasts along myeloid lineages in primary human AML xenograft models. AG-221 induces the differentiation.
Jacob Andrade, Shundi Ge, Goar Symbatyan, Michael S. Rosol, Arthur J

Jacob Andrade, Shundi Ge, Goar Symbatyan, Michael S. Rosol, Arthur J
The Requirement for Cyclin D Function in Tumor Maintenance

The Requirement for Cyclin D Function in Tumor Maintenance
A potent tetravalent T-cell–engaging bispecific antibody against CD33 in acute myeloid leukemia by Sayed Shahabuddin Hoseini, Hongfen Guo, Zhihao Wu, Miho.

A potent tetravalent T-cell–engaging bispecific antibody against CD33 in acute myeloid leukemia by Sayed Shahabuddin Hoseini, Hongfen Guo, Zhihao Wu, Miho.
Jacob Andrade, Shundi Ge, Goar Symbatyan, Michael S. Rosol, Arthur J

Jacob Andrade, Shundi Ge, Goar Symbatyan, Michael S. Rosol, Arthur J
Effects of SC144 on in vivo ovarian tumor.

Effects of SC144 on in vivo ovarian tumor.
Fig. 4. Antitumor efficacy of ERY974 against various cancer types.

Fig. 4. Antitumor efficacy of ERY974 against various cancer types.
Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.

Inhibition of FGFR signaling and tumor growth in SNU-16 xenograft model by administration of E7090. Inhibition of FGFR signaling and tumor growth in SNU-16.
Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.

Fig. 7 Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors. Gel scaffold for inhibition of postsurgical recurrence of B16F10 tumors.
Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.
Fig. 5 Local gel scaffold for T cell memory response.

Fig. 5 Local gel scaffold for T cell memory response.
Fig. 2. IL-2/rapamycin–expanded T cells express homing receptors to traffic to lymphoma sites and are resistant to SN-38 toxicity. IL-2/rapamycin–expanded.

Fig. 2. IL-2/rapamycin–expanded T cells express homing receptors to traffic to lymphoma sites and are resistant to SN-38 toxicity. IL-2/rapamycin–expanded.
Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in xenografted mice. Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in.

Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in xenografted mice. Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in.
by Nicholas J. Laping, Michael P. DeMartino, Joshua E

by Nicholas J. Laping, Michael P. DeMartino, Joshua E
Role of CYP3A4 in bone marrow microenvironment–mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors by Yu-Ting Chang, Daniela Hernandez,

Role of CYP3A4 in bone marrow microenvironment–mediated protection of FLT3/ITD AML from tyrosine kinase inhibitors by Yu-Ting Chang, Daniela Hernandez,
Serial vaccination with 32Dp210-derived whole cell vaccines in non-tumor-bearing mice stimulates robust antileukemic cytolytic activity. Serial vaccination.

Serial vaccination with 32Dp210-derived whole cell vaccines in non-tumor-bearing mice stimulates robust antileukemic cytolytic activity. Serial vaccination.

Similar presentations

Ads by Google